QUANTRO Therapeutics achieves breakthrough in transcriptomic drug discovery with first successful simultaneous 10-target multiplex-screening QUANTRO’s proprietary time-resolved functional transcriptomic discovery platform accelerates target screening for complex indications in oncology and inflammationQUANTRO CEO Dr. Michael Bauer to...

QUANTRO Therapeutics reaches a milestone in the collaboration with Boehringer Ingelheim to develop first-in-class cancer treatments VIENNA, Austria, June 04, 2024 (GLOBE NEWSWIRE) -- QUANTRO Therapeutics (QUANTRO), a pioneer in the discovery of first-in-class transcription factor targeting cancer treatments, announced today that...